307 related articles for article (PubMed ID: 15648188)
21. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
22. MRI screening for breast cancer in women with familial or genetic predisposition: design of the Dutch National Study (MRISC).
Kriege M; Brekelmans CT; Boetes C; Rutgers EJ; Oosterwijk JC; Tollenaar RA; Manoliu RA; Holland R; de Koning HJ; Klijn JG
Fam Cancer; 2001; 1(3-4):163-8. PubMed ID: 14574173
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
Tilanus-Linthorst MM; Obdeijn IM; Hop WC; Causer PA; Leach MO; Warner E; Pointon L; Hill K; Klijn JG; Warren RM; Gilbert FJ
Clin Cancer Res; 2007 Dec; 13(24):7357-62. PubMed ID: 18094417
[TBL] [Abstract][Full Text] [Related]
24. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing.
Murphy CD; Lee JM; Drohan B; Euhus DM; Kopans DB; Gadd MA; Rafferty EA; Specht MC; Smith BL; Hughes KS
Cancer; 2008 Dec; 113(11):3116-20. PubMed ID: 18932252
[TBL] [Abstract][Full Text] [Related]
25. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.
Griebsch I; Brown J; Boggis C; Dixon A; Dixon M; Easton D; Eeles R; Evans DG; Gilbert FJ; Hawnaur J; Kessar P; Lakhani SR; Moss SM; Nerurkar A; Padhani AR; Pointon LJ; Potterton J; Thompson D; Turnbull LW; Walker LG; Warren R; Leach MO;
Br J Cancer; 2006 Oct; 95(7):801-10. PubMed ID: 17016484
[TBL] [Abstract][Full Text] [Related]
27. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer.
Lord SJ; Lei W; Craft P; Cawson JN; Morris I; Walleser S; Griffiths A; Parker S; Houssami N
Eur J Cancer; 2007 Sep; 43(13):1905-17. PubMed ID: 17681781
[TBL] [Abstract][Full Text] [Related]
28. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
Chompret A
J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
[TBL] [Abstract][Full Text] [Related]
29. MRI in the early detection of breast cancer in women with high genetic risk.
Trecate G; Vergnaghi D; Manoukian S; Bergonzi S; Scaperrotta G; Marchesini M; Ferranti C; Peissel B; Spatti G; Bohm S; Conti A; Costa C; Sporeni M; Podo F; Musumeci R
Tumori; 2006; 92(6):517-23. PubMed ID: 17260493
[TBL] [Abstract][Full Text] [Related]
30. Familial breast and ovarian cancers.
Arai M; Utsunomiya J; Miki Y
Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
[TBL] [Abstract][Full Text] [Related]
31. Screening and follow-up of the patient at high risk for breast cancer.
Willey SC; Cocilovo C
Obstet Gynecol; 2007 Dec; 110(6):1404-16. PubMed ID: 18055740
[TBL] [Abstract][Full Text] [Related]
32. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
[TBL] [Abstract][Full Text] [Related]
33. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
[TBL] [Abstract][Full Text] [Related]
35. Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study.
Evans DG; Lennard F; Pointon LJ; Ramus SJ; Gayther SA; Sodha N; Kwan-Lim GE; Leach MO; Warren R; Thompson D; Easton DF; Eeles R;
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2123-31. PubMed ID: 19567506
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
Gronwald J; Tung N; Foulkes WD; Offit K; Gershoni R; Daly M; Kim-Sing C; Olsson H; Ainsworth P; Eisen A; Saal H; Friedman E; Olopade O; Osborne M; Weitzel J; Lynch H; Ghadirian P; Lubinski J; Sun P; Narod SA;
Int J Cancer; 2006 May; 118(9):2281-4. PubMed ID: 16331614
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]